Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease Rapid Communication

Kidney International

Volumn 52, Issue 6, 1997, Pages 1685-1692

  Trenkwalder, Evi ^b   Gruber, Alexandra ^b   König, Paul ^b   Dieplinger, Hans ^b   Kronenberg, Florian ^a  

^a Inst of Med Biol and Hum Genet   (Austria)

^b NONE

Author keywords

Atherosclerosis; End stage renal disease; Glycoprotein apolipoprotein(a); Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031435455     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.503     Document Type: Article

References (53)

1. UTERMANN G, MENZEL HJ, KRAFT HG, DUBA HC, KEMMLER HG, SEITZ C: Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80:458-465, 1987
2. LACKNER C, BOERWINKLE E, LEFFERT CC, RAHMIG T, HOBBS HH: Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87:2153-2161, 1991
3. BOERWINKLE E, LEFFERT CC, LIN J, LACKNER C, CHIESA G, HOBBS HH: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90:52-60, 1992
4. KRAFT HG, KÖCHL S, MENZEL HJ, SANDHOLZER C, UTERMANN G: The apolipoprotein(a) gene: A transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 90:220-230, 1992
5. KRONENBERG F, STEINMETZ A, KOSTNER GM, DIEPLINGER H: Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 33:495-543, 1996
6. RADER DJ, HOEG JM, BREWER HB JR: Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120:1012-1025, 1994
7. KRONENBERG F, UTERMANN G, DIEPLINGER H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27:1-25, 1996
8. LONDON GM, DRÜEKE TB: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51:1678-1695, 1997
9. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O'NEIL J, SKIBINSKI CI, HOFF HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
10. KRONENBERG F, KATHREIN H, KÖNIG P, NEYER U, STURM W, LHOTTA K, GRÖCHENIG E, UTERMANN G, DIEPLINGER H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411, 1994
11. WANNER C, BARTENS W, WALZ G, NAUCK M, SCHOLLMEYER P: Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 10:75-81, 1995
12. WEBB AT, REAVELEY DA, O'DONNELL M, O'CONNOR B, SEED M, BROWN EA: Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10:354-357, 1995
13. KOCH M, KUTKUHN B, TRENKWALDER E, BACH D, GRABENSEE B, DIEPLINGER H, KRONENBERG F: ApoB, fibrinogen, HDL cholesterol and apo(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol (in press)
14. BLACK IW, WILCKEN DEL: Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin Chem 38:353-357, 1992
15. KRONENBERG F, KÖNIG P, LHOTTA K, ÖFNER D, SANDBOLZER C, MARGREITER R, DOSCH E, UTERMANN G, DIEPLINGER H: Apolipoprotein(a) phenotype associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Anterioscler Thromb 14: 1399-1404, 1994
16. OIDA K, TAKAI H, MAEDA H, TAKAHASHI S, SHIMADA A, SUZUKI J, TAMAI T, NAKAI T, MIYABO S: Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 38:2244-2248, 1992
17. MOOSER V, SEABRA MC, ABEDIN M, LANDSCHULZ KT, MARCOVINA S, HOBBS HH: Apolipoprotein(a) kringle 4-containing fragments in urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 97:858-864, 1996
18. KOSTNER KM, MAURER G, HUBER K, STEFENELLI T, DIEPLINGER H, STEYRER E, KOSTNER GM: Urinary excretion of apo(a) fragments -Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 16:905-911, 1996
19. KRONENBERG F, TRENKWALDER E, LINGENHEL A, FRIEDRICH G, LHOTTA K, SCHOBER M, MOES N, KÖNIG P, UTERMANN G, DIEPLINGER H: Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J Lipid Res 38:1755-1763, 1997
20. MOOSER V, MARCOVINA SM, WHITE AL, HOBBS HH: Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 98:2414-2424, 1996
21. WHITE AL, LANFORD RE: Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol 6:75-80, 1995
22. BRUNNER C, KRAFT HG, UTERMANN G, MÜLLER HJ: Cys(4057) of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 90:11643-11647, 1993
23. FRANK S, DUROVIC S, KOSTNER GM: The assembly of lipoprotein Lp(a). Eur J Clin Invest 26:109-114, 1996
24. DIEPLINGER H, GRUBER G, KRASZNAI K, RESCHAUER S, SEIDEL C, BURNS G, MÜLLER H-J, CSÁSZÁR A, VOGEL W, ROBENEK H, UTERMANN G: Kringle 4 of human apolipoprotein[a] shares a linear antigenic site with human catalase. J Lipid Res 36:813-822, 1995
25. KRONENBERG F, LOBENTANZ E-M, KÖNIG P, UTERMANN G, DIEPLINGER H: Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides. J Lipid Res 35:1318-1328, 1994
26. DIEPLINGER H, LACKNER C, KRONENBERG F, SANDHOLZER C, LHOTTA K, HOPPICHLER F, GRAF H, KÖNIG P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91:397-401, 1993
27. DIEPLINGER H, LOBENTANZ E-M, KÖNIG P, GRAF H, SANDHOLZER C, MATTHYS E, ROSSENEU M, UTERMANN G: Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease. Eur J Clin Invest 22:166-174, 1992
28. KAMBOH MI, FERRLL RE, KOTTKE BA: Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 49:1063-1074, 1991
29. BUDOWLE B, GIUSTI AM, WAYE JS, BAECHTEL FS, FOURNEY RM, ADAMS DE, PRESLEY LA, DEADMAN HA, MONSON KL: Fixed-bin analysis for statistical evaluation of continuous distributions of allelic data from VNTR loci, for use in forensic comparisons. Am J Hum Genet 48:841-855, 1991
30. SANDHOLZER C, SAHA N, KARK JD, REES A, JAROSS W, DIEPLINGER H, HOPPICHLER F, BOERWINKLE E, UTERMANN G: Apo(a) isoforms predict risk for coronary heart disease: A study in six populations. Arterioscler Thromb 12:1214-1226, 1992
31. MÖLGAARD J, KLAUSEN IC, LASSVIK C, FÆRGEMAN O, GERDES LU, OLSSON AG: Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 12:895-901, 1992
32. KRONENBERG F, KÖNIG P, NEYER U, AUINGER M, PRIBASNIG A, LANG U, REITINGER J, PINTER G, UTERMANN G, DIEPLINGER H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
33. WILD SH, FORTMANN SP, MARCOVINA SM: A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol 17:239-245, 1997
34. KOSCHINSKY ML, BEISIEGEL U, HENNE-BRUNS D, EATON DL, LAWN RM: Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochemistry 29:640-644, 1990
35. AZROLAN N, BROWN CD, THOMAS L, HAYEK T, ZHAO ZH, ROBERTS KG, SCHEINER C, FRIEDMAN EA: Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler Thromb 14:1393-1398, 1994
36. EDWARDS BD, BHATNAGAR D, MACKNESS MI, GOKAL R, BALLARDIE FW, CHALMERS RJG, DURRINGTON PN: Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. Q J Med 88:109-113, 1995
37. HUNT BJ, PARRATT R, ROSE M, YACOUB M: Does cyclosporin affect lipoprotein(a) concentrations? Lancet 343:119-120, 1994
38. STURROCK NDC, LANG CC, MACFARLANE LJ, DOKKRELL MEC, RYAN M, WEBB DJ, STRUTHERS AD: Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 13:667-673, 1995
39. WHITE AL, LANFORD RE: Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatoeytes. J Biol Chem 269:28716-28723, 1994
40. KOSCHINSKY ML, TOMLINSON JE, ZIONCHECK TF, SCHWARTZ K, EATON DL, LAWN RM: Apolipoprotein(a): Expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry 30:5044-5051, 1991
41. FRANK S, KRASZNAI K, DUROVIC S, LOBENTANZ EM, DIEPLINGER H, WAGNER E, ZATLOUKAL K, COTTEN M, UTERMANN G, KOSTNER GM, ZECHNER R: High-level expression of various apolipoprotein(a) isoforms by "transferrinfection": The role of kringle IV sequences in the extracellular association with low-density lipoprotein. Biochemistry 33:12329-12339, 1994
42. STEYRER E, DUROVIC S, FRANK S, GIESSAUF W, BURGER A, DIEPLINGER H, ZECHNER R, KOSTNER GM: The role of lecithin: cholesterol acyltransferase for lipoprotein(a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 94:2330-2340, 1994
43. 3500→Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low density lipoproteins. J Biol Chem 269:30320-30325, 1994
44. MENZEL H-J, DIEPLINGER H, LACKNER C, HOPPICHLER F, LLOYD JK, MULLER DR, LABEUR C, TALMUD PJ, UTERMANN G: Abetalipoproteinemia with an apoB-100-lipoprotein(a) glycoprotein complex in plasma: Indication for an assembly defect. J Biol Chem 265:981-986, 1990
45. DIEPLINGER H, SCHOENFELD PY, FIELDING J: Plasma cholesterol metabolism in end-stage renal disease: Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 77:1071-1083, 1986
46. ATTMAN P-O, ALAUPOVIC P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 39(Suppl 31):S16-S23, 1991
47. MAGGI E, BELLAZZI R, FALASCHI F, FRATTONI A, PERANI G, FINARDI G, GAZO A, NAI M, ROMANINI D, BELLOMO G: Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis. Kidney Int 45:876-883, 1994
48. HÖRKKÖ S, HUTTUNEN K, KISÄNIEMI YA: Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 47:1732-1740, 1995
49. BUCALA R, MAKITA Z, VEGA G, GRUNDY S, KOSCHINSKY T, CERAMI A, VLASSARA H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445, 1994
50. SCHAEFER JR, RADER DJ, BREWER HB JR: Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. Curr Opin Lipidol 3:227-232, 1992
51. CALLOW MJ, VERSTUYFT J, TANGIRALA R, PALINSKI W, RUBIN EM: Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 96:1639-1646, 1995
52. RATH M, NIENDORE A, REBLIN T, DIETEL M, KREBBER H-J, BEISIEGEL U: Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579-592, 1989
53. PEPIN JM, O'NEIL JA, HOFF HF: Quantification of upo[a] and apoB in human atherosclerotic lesions. J Lipid Res 32:317-327, 1991